AI Summary
The addition of immune checkpoint blockade to perioperative therapy increases treatment-related adverse events and discontinuation of treatment. Close monitoring of patients for adverse events is necessary in earlier-stage settings.
The addition of immune checkpoint blockade to perioperative therapy was associated with an increase in grade 3–4 treatment-related adverse events and adverse events leading to treatment discontinuation. These findings provide safety insights for further clinical trials assessing neoadjuvant or adjuvant immune checkpoint blockade therapy. Clinicians should closely monitor patients for treatment-related adverse events to prevent treatment discontinuations and morbidity from these therapies in earlier-stage settings.